Markus J. Cappel Sells 30,237 Shares of ChemoCentryx Inc (CCXI) Stock

Share on StockTwits

ChemoCentryx Inc (NASDAQ:CCXI) insider Markus J. Cappel sold 30,237 shares of the stock in a transaction that occurred on Friday, October 26th. The stock was sold at an average price of $11.01, for a total value of $332,909.37. Following the transaction, the insider now directly owns 54,063 shares of the company’s stock, valued at $595,233.63. The sale was disclosed in a filing with the SEC, which is available at this link.

NASDAQ CCXI traded up $1.03 during mid-day trading on Tuesday, hitting $11.42. The stock had a trading volume of 391,400 shares, compared to its average volume of 271,520. ChemoCentryx Inc has a 52-week low of $5.42 and a 52-week high of $15.08. The company has a market capitalization of $551.40 million, a P/E ratio of 30.92 and a beta of 1.55. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.69 and a quick ratio of 2.69.

ChemoCentryx (NASDAQ:CCXI) last released its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. ChemoCentryx had a return on equity of 39.31% and a net margin of 18.69%. The firm had revenue of $15.02 million during the quarter, compared to the consensus estimate of $16.88 million. On average, research analysts expect that ChemoCentryx Inc will post -0.86 earnings per share for the current fiscal year.

CCXI has been the subject of a number of analyst reports. BidaskClub raised ChemoCentryx from a “hold” rating to a “buy” rating in a research note on Thursday, August 30th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of ChemoCentryx in a research note on Monday, August 13th. ValuEngine raised ChemoCentryx from a “hold” rating to a “buy” rating in a research note on Friday, August 10th. Canaccord Genuity reaffirmed a “buy” rating and issued a $18.00 price objective on shares of ChemoCentryx in a research note on Friday, August 10th. Finally, Zacks Investment Research downgraded ChemoCentryx from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 16th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. ChemoCentryx currently has a consensus rating of “Buy” and a consensus target price of $16.58.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CCXI. Schwab Charles Investment Management Inc. increased its stake in ChemoCentryx by 22.4% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 43,100 shares of the biopharmaceutical company’s stock valued at $587,000 after purchasing an additional 7,900 shares in the last quarter. JPMorgan Chase & Co. increased its stake in ChemoCentryx by 278.8% in the 1st quarter. JPMorgan Chase & Co. now owns 67,861 shares of the biopharmaceutical company’s stock valued at $923,000 after purchasing an additional 49,944 shares in the last quarter. Russell Investments Group Ltd. increased its stake in ChemoCentryx by 57.5% in the 1st quarter. Russell Investments Group Ltd. now owns 65,071 shares of the biopharmaceutical company’s stock valued at $885,000 after purchasing an additional 23,745 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in ChemoCentryx by 140.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 20,352 shares of the biopharmaceutical company’s stock valued at $276,000 after purchasing an additional 11,902 shares in the last quarter. Finally, Barclays PLC increased its stake in ChemoCentryx by 193.9% in the 1st quarter. Barclays PLC now owns 13,066 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 8,621 shares in the last quarter. 53.23% of the stock is owned by hedge funds and other institutional investors.

About ChemoCentryx

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).

See Also: Understanding Compound Annual Growth Rate (CAGR)

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply